Thoracic duct scintigraphy by orally administered I-123 BMIPP with SPECT/CT for the prevention of thoracic duct injury at the thoracic surgery for the the esophageal cancer

Thoracic duct scintigraphy by orally administered I-123 BMIPP with SPECT/CT for the prevention of thoracic duct injury at the thoracic surgery for the the esophageal cancer - Thoracic duct scintigraphy by orally administered I-123 BMIPP with SPECT/CT

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003757

Enrollment

Registered

2011-04-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

SPECT CT scanning after the orally administration of BMIPP 111MBq.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Preoperative patients with esophageal cancer.

Exclusion criteria

Exclusion criteria: Informed consent was not obtained from the patients.

Design outcomes

Primary

Measure	Time frame
Rate of visualization of the thoracic duct by the thoracic duct scintigraphy. Difference among the findings of the thoracic duct scitigraphy, the other imaging modalities, and the surgical findings.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026